Table 2.
Resection rate after FOLFOXIRI vs FOLFIRI/FOLFOX in the first-line treatment of metastatic colorectal cancer in randomized–controlled clinical trials
| Author (study name, year) | Trial phase | Study population | Treatment arms | No. of patients | Median age (range), years | PS 0 (%) | CRC patients with LM only (%) | ORR (%) | Resection (%) | R0 resection (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Souglakos et al. [7] (HORG, 2006) | III |
Age ≥18 years ECOG PS 0–2 |
FOLFOXIRI | 138 | 66 (25–82) | 36% | NR | 43% | 10% | 9% |
| FOLFIRI | 147 | 66 (39–84) | 38% | NR | 34% | 4% | 3% | |||
| Falcone et al. [4] (GONO, 2007) | III |
Age of 18–75 years ECOG PS 0–2 (18–70 years) ECOG PS 0 (71–75 years) |
FOLFOXIRI | 122 | 62 (27–75) | 61% | 34% | 66% | NR |
All: 15% LM only: 36% |
| FOLFIRI | 122 | 64 (21–75) | 61% | 32% | 41% | NR |
All: 6% LM only: 12% |
|||
| Ychou et al. [14] (METHEP, 2013) | II | Initially unresectable or not optimally resectable liver metastases | FOLFIRINOX | 30 | 64 (43–74) | 77% | 100% | 73% | 67% | 30% |
| FOLFOX/FOLFIRI | 30 | 63 (43–73) | 72% | 100% | 60% | 40% | 23% | |||
| Gruenberger et al. [15] (OLIVIA, 2015) | II |
Age ≥18 years ECOG PS 0–1 Initially unresectable liver metastases |
FOLFOXIRI + bev | 41 | 63 (32–77) | 56% | 100% | 81% | 61% | 49% |
| FOLFIRI + bev | 39 | 57 (28–80) | 80% | 100% | 62% | 49% | 23% | |||
| Cremolini et al. [5] (TRIBE, 2014) | III |
Age 18–75 years ECOG PS 0–2 (18–70 years) ECOG PS 0 (71–75 years) |
FOLFOXIRI + bev | 252 | 61 (29–75) | 90% | 23% | 65% | NR | 15% |
| FOLFIRI + bev | 256 | 60 (29–75) | 90% | 18% | 53% | NR | 12% | |||
| Hurwitz et al. [8] (STEAM, 2019) | II |
Age of 18–75 years ECOG PS 0–2 (18–70 years) ECOG PS 0 (71–75 years) |
FOLFOXIRI + bev | 93 | 58 (23–75) | 67% | 30% | 72% | 17% | 16% |
| FOLFIRI + bev | 95 | 58 (34–73) | 54% | 28% | 62% | 8% | 6% | |||
| Cremolini et al. [6] (TRIBE2, 2020) | III |
Age of 18–75 years ECOG PS 0–2 (18–70 years) ECOG PS 0 (71–75 years) |
FOLFOXIRI + bev | 339 | 60 (53–67) | 86% | 31% | 62% | NR | 17% |
| FOLFOX + bev | 340 | 61 (52–67) | 85% | 28% | 50% | NR | 12% |
FOLFOXIRI, 5-Fluorouracil + Oxaliplatin + Irinotecan; FOLFIRI, 5-Fluorouracil + Irinotecan; FOLFOX, 5-Fluorouracil + Oxaliplatin; bev, bevacizumab; ORR, objective response rate; ECOG PS, Eastern Cooperative Oncology Group performance status; CRC, colorectal cancer; LM, liver metastasis; NR, not reported.